DaVita, in a U.S. Securities and Exchange Commission filing last week, indicated that while Optum will continue with its planned purchase of DaVita, it will carve out the Nevada clinics, helping reduce the price of its purchase to $4.34 billion.
DaVita, in a U.S. Securities and Exchange Commission filing last week, indicated that while Optum will continue with its planned purchase of DaVita, it will carve out the Nevada clinics, helping reduce the price of its purchase to $4.34 billion.